Charles River Laboratories International (NYSE:CRL) Announces Quarterly Earnings Results

Charles River Laboratories International (NYSE:CRL) released its quarterly earnings data on Wednesday. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.25, Briefing.com reports. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the firm posted $3.12 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International updated its FY 2026 guidance to 11.150-11.450 EPS.

Here are the key takeaways from Charles River Laboratories International’s conference call:

• Charles River raised its 2026 outlook, now projecting flat to 1% organic revenue growth and non-GAAP EPS of $11.15–$11.45, up $0.25 at the midpoint from prior guidance.
• DSA demand improved materially, with second-quarter net bookings rising 12.6% sequentially to $701 million, backlog reaching $1.97 billion, and net book-to-bill increasing to 1.19 times. Management expects DSA organic growth to accelerate in the second half.
• Portfolio divestitures and lower non-human-primate sourcing costs are expected to drive at least 500 basis points of operating-margin improvement in the second half, while manufacturing margins are expected to approach 40%.
• RMS revenue declined 1.4% organically, pressured by weaker North American research-model volumes and constrained academic and government spending; management continues to forecast a low- to mid-single-digit organic decline for the segment in 2026.
• A higher expected tax rate of 23%–24%, partly tied to proposed legislation in Mauritius, is expected to create an approximately $0.20 per-share EPS headwind for the year, although a lower-than-expected change could provide upside.

Charles River Laboratories International Price Performance

CRL stock traded down $3.67 during trading on Friday, hitting $261.85. The stock had a trading volume of 266,031 shares, compared to its average volume of 921,884. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.03 and a current ratio of 1.35. The stock has a market cap of $12.61 billion, a price-to-earnings ratio of -53.93, a price-to-earnings-growth ratio of 2.86 and a beta of 1.38. The company’s 50 day moving average price is $213.14 and its two-hundred day moving average price is $188.71. Charles River Laboratories International has a 1-year low of $144.26 and a 1-year high of $268.00.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Sanford C. Bernstein set a $250.00 target price on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Barclays reaffirmed an “overweight” rating and set a $300.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research report on Monday, July 20th. Finally, BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a report on Wednesday, July 1st. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $246.69.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,264,241. This trade represents a 51.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International

Hedge funds and other institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its holdings in shares of Charles River Laboratories International by 14.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 744 shares of the medical research company’s stock valued at $150,000 after acquiring an additional 94 shares during the period. DRW Securities LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at $211,000. Metis Global Partners LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at $213,000. Certuity LLC purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $255,000. Finally, Osaic Holdings Inc. increased its holdings in shares of Charles River Laboratories International by 24.7% in the 2nd quarter. Osaic Holdings Inc. now owns 1,091 shares of the medical research company’s stock valued at $165,000 after purchasing an additional 216 shares during the period. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.